litlas
Log inCreate account

Michael R. Lassen

Active 1989–2021

31
Papers
24,628
Citations
31
h-index
31
i10-index

Citations

Citations per year for Michael R. Lassen1989: 1 citations1991: 2 citations1992: 4 citations1993: 5 citations1994: 4 citations1995: 6 citations1996: 2 citations1997: 2 citations1998: 12 citations1999: 5 citations2000: 9 citations2001: 17 citations2002: 44 citations2003: 43 citations2004: 69 citations2005: 87 citations2006: 80 citations2007: 125 citations2008: 135 citations2009: 214 citations2010: 289 citations2011: 255 citations2012: 277 citations2013: 242 citations2014: 168 citations2015: 130 citations2016: 133 citations2017: 122 citations2018: 81 citations2019: 448 citations2020: 416 citations2021: 379 citations2022: 269 citations2023: 172 citations2024: 297 citations2025: 62 citations2026: 1 citations1990: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,335 citing papers, 22.1% of this breakdownCanada: 547 citing papers, 9.1% of this breakdownUnited Kingdom: 482 citing papers, 8% of this breakdownGermany: 386 citing papers, 6.4% of this breakdownItaly: 358 citing papers, 5.9% of this breakdownFrance: 278 citing papers, 4.6% of this breakdownNetherlands: 278 citing papers, 4.6% of this breakdownChina: 195 citing papers, 3.2% of this breakdownSpain: 173 citing papers, 2.9% of this breakdownSwitzerland: 158 citing papers, 2.6% of this breakdownJapan: 153 citing papers, 2.5% of this breakdownSweden: 146 citing papers, 2.4% of this breakdown
0%22.1%Other 25.7%

Institutions

Fields

  • Medicine93.6%
  • Health Professions1.5%
  • Biochemistry, Genetics and Molecular Biology1.4%
  • Immunology and Microbiology0.9%
  • Pharmacology, Toxicology and Pharmaceutics0.8%
  • Engineering0.8%
  • Other1%

Topics

  • Venous Thromboembolism Diagnosis and Management21.7%
  • Atrial Fibrillation Management and Outcomes13.9%
  • Blood Coagulation and Thrombosis Mechanisms5.9%
  • Heparin-Induced Thrombocytopenia and Thrombosis4.1%
  • Antiplatelet Therapy and Cardiovascular Diseases3.2%
  • Central Venous Catheters and Hemodialysis2.7%
  • Other48.5%

Coauthors

All papers

Open in search
  1. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients

    Authors: Sam Schulman, Ulf Angerås, David Bergqvist, Bengt O. Eriksson, Michael R. Lassen, Winfield S. Fisher - Journal of Thrombosis and Haemostasis 2009 cited by 3,759

  2. Milvexian for the Prevention of Venous Thromboembolism

    Authors: Jeffrey I. Weitz, John Strony, Walter Ageno, David Gailani, Elaine M. Hylek, Michael R. Lassen, Kenneth W. Mahaffey, Ravi S. Notani, Robin Roberts, Annelise Segers, Gary E. Raskob - New England Journal of Medicine 2021 cited by 248

  3. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty

    Authors: Jeffrey I. Weitz, Rupert Bauersachs, Bastian Becker, Scott D. Berkowitz, Maria Cecília S. Freitas, Michael R. Lassen, Carola Metzig, Gary E. Raskob - JAMA 2020 cited by 249

  4. Prevention of Venous Thromboembolism

    Authors: William Geerts, Graham F. Pineo, John A. Heit, David Bergqvist, Michael R. Lassen, Clifford W. Colwell, Joel G. Ray - CHEST Journal 2004 cited by 5,912

  5. Prevention of Venous Thromboembolism

    Authors: William Geerts, David Bergqvist, Graham F. Pineo, John A. Heit, Charles Marc Samama, Michael R. Lassen, Clifford W. Colwell - CHEST Journal 2008 cited by 3,812

  6. Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement

    Authors: Michael R. Lassen, Alexander Gallus, Gary E. Raskob, Graham F. Pineo, Dalei Chen, Luz M. Ramirez - New England Journal of Medicine 2010 cited by 775

  7. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

    Authors: Michael R. Lassen, Gary E. Raskob, Alexander Gallus, Graham F. Pineo, Dalei Chen, Philip Hornick - The Lancet 2010 cited by 777

  8. Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty

    Authors: Michael R. Lassen, Walter Ageno, Lars C. Borris, Jay R. Lieberman, Nadia Rosencher, Tiemo J. Bandel, Frank Misselwitz, Alexander G.G. Turpie - New England Journal of Medicine 2008 cited by 1,296

  9. Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer

    Authors: Giancarlo Agnelli, Daniel J. George, Ajay K. Kakkar, William Fisher, Michael R. Lassen, Patrick Mismetti, Patrick Mouret, Umesh Chaudhari, Francesca Lawson, Alexander G.G. Turpie - New England Journal of Medicine 2012 cited by 533

  10. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

    Authors: Alexander GG Turpie, Michael R. Lassen, Bruce L. Davidson, Kenneth A. Bauer, Michael Gent, Louis M. Kwong, Fred D. Cushner, Paul A. Lotke, Scott D. Berkowitz, Tiemo J. Bandel, Alice Benson, Frank Misselwitz, William D. Fisher - The Lancet 2009 cited by 979

  11. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial

    Authors: Alexander T Cohen, Bruce L. Davidson, Alexander Gallus, Michael R. Lassen, Martin H. Prins, Witold Tomkowski, Alexander G.G. Turpie, Jan F M Egberts, Anthonie W.A. Lensing - BMJ 2006 cited by 861

  12. Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement

    Authors: Michael R. Lassen, Gary E. Raskob, Alexander Gallus, Graham F. Pineo, Dalei Chen, Ronald J. Portman - New England Journal of Medicine 2009 cited by 694

  13. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement

    Authors: Michael R. Lassen, Bruce L. Davidson, Alexander Gallus, Graham F. Pineo, Jack Ansell, David Deitchman - Journal of Thrombosis and Haemostasis 2007 cited by 370

  14. Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee Surgery

    Authors: Kenneth A. Bauer, Bengt I. Eriksson, Michael R. Lassen, Alexander G.G. Turpie - New England Journal of Medicine 2001 cited by 661

  15. Prevention and Treatment of Venous Thromboembolism

    Authors: Aliki Nicolaides, Jawed Fareed, A.K. Kakkar, A. J. Comerota, Samuel Z. Goldhaber, Russel Hull, Kenneth A. Myers, Meyer‐Michel Samama, Jacqueline Fletcher, Evi Kalodiki, David Bergqvist, J. Bonnar, Joseph A. Caprini, C. Carter, J Conard, B Eklöf, Ismaı̈l Elalamy, Grigoris Gerotziafas, George Geroulakos, A. Giannoukas, Ian A. Greer, Maryclare Griffin, S. Kakkos, Michael R. Lassen, Gordon Lowe, Arie Markel, Paolo Prandoni, G. Raskob, Alex C. Spyropoulos, Alexander G.G. Turpie, Jeanine M. Walenga, David Warwick - Clinical and Applied Thrombosis/Hemostasis 2013 cited by 186

  16. Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Hip-Fracture Surgery

    Authors: Bengt I. Eriksson, Kenneth A. Bauer, Michael R. Lassen, Alexander G.G. Turpie - New England Journal of Medicine 2001 cited by 633

  17. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial

    Authors: Alexander GG Turpie, Kenneth A. Bauer, Bengt I. Eriksson, Michael R. Lassen - The Lancet 2002 cited by 534

  18. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison

    Authors: Michael R. Lassen, Kenneth A. Bauer, Bengt I. Eriksson, Alexander GG Turpie - The Lancet 2002 cited by 403

  19. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement

    Authors: Gary E. Raskob, Alexander Gallus, Graham F. Pineo, Dongyang Chen, L-M. Ramirez, Richard T. Wright, Michael R. Lassen - Journal of Bone and Joint Surgery - British Volume 2012 cited by 98

  20. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty

    Authors: Michael R. Lassen, Bengt I. Eriksson, Michael Gent, Scott D. Berkowitz, Frank Misselwitz, Tiemo J. Bandel, Martin Homering, Torsten Westermeier, Ajay K. Kakkar, Alexander G.G. Turpie - Thrombosis and Haemostasis 2010 cited by 268

  21. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study

    Authors: Bengt I. Eriksson, Giancarlo Agnelli, Alexander T. Cohen, O.E. Dahl, Michael R. Lassen, Patrick Mouret, Nadia Rosencher, Peter Kälebo, Seva Panfilov, Christina Eskilson, Magnus Andersson - Journal of Thrombosis and Haemostasis 2003 cited by 199

  22. ORIGINAL ARTICLE: Soluble Human Leukocyte Antigen‐G Isoforms in Maternal Plasma in Early and Late Pregnancy

    Authors: Roberta Rizzo, Anita Sylvest Andersen, Michael R. Lassen, Helle Christina Sørensen, Thomas Bergholt, Margit Hørup Larsen, Loredana Melchiorri, Marina Stignani, Olavio R. Baricordi, Thomas Vauvert F. Hviid - American Journal of Reproductive Immunology 2009 cited by 104

  23. Use of the Low-Molecular-Weight Heparin Reviparin to Prevent Deep-Vein Thrombosis after Leg Injury Requiring Immobilization

    Authors: Michael R. Lassen, Lars C. Borris, Roumen Nakov - New England Journal of Medicine 2002 cited by 201

  24. Prevention And Treatment Of Venous Thromboembolism : International Consensus Statement

    Authors: Andrew Nicolaides, Jawed Fareed, A.K. Kakkar, A. J. Comerota, Samuel Z. Goldhaber, Russell D. Hull, K Myers, M Samama, John Fletcher, Evi Kalodiki, David Bergqvist, J. Bonnar, Joseph A. Caprini, C Carter, J Conard, B Eklöf, Ismaı̈l Elalamy, Grigoris Gerotziafas, George Geroulakos, Athanasios Giannoukas, Ian A. Greer, Maura Griffin, Stavros K. Kakkos, Michael R. Lassen, G.D.O. Lowe, Arie Markel, Paolo Prandoni, Gary E. Raskob, Alex C Spyropoulos, A. G. G. Turpie, Jeanine M. Walenga, David Warwick - International Journal of Angiology 2013 cited by 194